ArticleGut1997
Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate.
Article in Gut, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Renal manifestations in inflammatory bowel disease: a systematic review.Journal of gastroenterology · 2022Pooled it
- No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases.International journal of colorectal disease · 2003Trial
- Trial
- Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.British journal of clinical pharmacology · 2000Trial
- Inflammatory bowel disease and renal disorders: from clinical associations to shared mechanisms and management strategies.Frontiers in immunology · 2026Review
- Oral inulin prebiotic encapsulatingTheranostics · 2026Article
- Proximal Tubule Dysfunction Secondary to Salicylate Intoxication.Global pediatric health · 2022Article
- Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020Article
- Beneficial effect of Amorphophallus paeoniifolius tuber on experimental ulcerative colitis in rats.Pharmaceutical biology · 2017Article
- Tubulointerstitial nephritis: diagnosis, treatment, and monitoring.Pediatric nephrology (Berlin, Germany) · 2017Review
- Current application of proteomics in biomarker discovery for inflammatory bowel disease.World journal of gastrointestinal pathophysiology · 2016Review
- Five-aminosalicylic Acid: an update for the reappraisal of an old drug.Gastroenterology research and practice · 2015Review
- Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatment.Frontline gastroenterology · 2015Article
- Naringin ameliorates acetic acid induced colitis through modulation of endogenous oxido-nitrosative balance and DNA damage in rats.Journal of biomedical research · 2014Article
- Evaluation of nephroprotective and immunomodulatory activities of antioxidants in combination with cisplatin against murine visceral leishmaniasis.PLoS neglected tropical diseases · 2012Article
- Renal effects of long-term treatment with 5-aminosalicylic acid.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2009Article
- Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Clinical and experimental gastroenterology · 2009Article
- Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?World journal of gastroenterology · 2006Article
- Urinary protein analysis in pre- and postoperative cancer patients.Journal of clinical laboratory analysis · 2005Article
- Interstitial nephritis from mesalazine: case report and literature review.Pediatric nephrology (Berlin, Germany) · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn increasing number of case reports indicate potential nephrotoxicity of 5-aminosalicylic acid (5-ASA), which shares similarities with the chemical structures of both phenacetin and acetylsalicylic acid.
aimIn a point prevalence study the occurrence of sensitive indices indicative of early kidney malfunction was assessed in outpatients with inflammatory bowel disease.
methodsRoutine indices of kidney function (creatinine clearance, urinary protein content, pH, electrolytes, and microscopy) were investigated in 223 patients with inflammatory bowel disease as well as sensitive markers of glomerular or tubular dysfunction (microproteinuria by SDS polyacrylamide gel electrophoresis (SDS-PAGE), urinary concentrations of N-acetyl-beta-D-glucosaminidase, alpha 1-microglobulin, gamma-glutamyltransferase (GGT), alkaline phosphatase (AP), and albumin). Histories of exposure to 5-ASA were assessed by questionnaire.
resultsPatients receiving high amounts of 5-ASA, both actual as well as on a lifetime basis, showed an increased prevalence of tubular proteinuria by SDS-PAGE. Raised values for urinary AP and GGT indicate proximal tubular epithelial cells as the source. All other kidney function tests were normal. Analysis of covariates indicated strong associations between disease activity and size of 5-ASA doses as well as alterations in kidney tubular function.
conclusionThe possibility exists that high doses of 5-ASA may be associated with proximal tubular proteinuria. This point prevalence study cannot dissect the possible impact of chronic inflammation from high dose 5-ASA treatment and further prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.